Why The Story Around Trulieve Cannabis (CNSX:TRUL) Is Shifting With New Valuation Assumptions
Trulieve Cannabis is back in focus after an updated fair value estimate edges from CA$19.53 to CA$20.36, a measured reset rather than a sweeping overhaul. That shift lines up with broader Street …
Assessing Trulieve Cannabis (CNSX:TRUL) Valuation After New Dabstract Partnership And Recent Share Price Moves
Why the Dabstract partnership matters for Trulieve Cannabis The latest move driving attention to Trulieve Cannabis (CNSX:TRUL) is its new partnership with concentrate brand Dabstract to bring High …
NewLake Capital Partners: Collect A Double-Digit Yield From This Cannabis Landlord
NewLake Capital Partners (NLCP) offers a near-12% yield with strong occupancy, low debt and rising dividends—an overlooked cannabis REIT.
Canadians could claim part of $8-million cannabis settlement
Canadians who invested in cannabis stock could cash in on a hefty class-action settlement against Wayland Group Corp.
Cannabis stocks on track for best week of 2026 as FDA loosens CBD enforcement
Tilray Brands, Canopy Growth, and Curaleaf Holdings stocks are surging after the FDA says it won’t enforce some regulations for CBD products.
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
Canadians could claim part of $8-million cannabis settlement
Canadians who invested in cannabis stock could cash in on a hefty class-action settlement against Wayland Group Corp.
Cannabis stocks on track for best week of 2026 as FDA loosens CBD enforcement
Tilray Brands, Canopy Growth, and Curaleaf Holdings stocks are surging after the FDA says it won’t enforce some regulations for CBD products.
Tilray Brands’ strong cannabis sales and upbeat outlook keeps Jefferies analysts bullish
Tilray Inc (NASDAQ:TLRY) earned a repeat ‘Buy’ rating from Jefferies analysts after what it described as a solid third quarter earnings report, pointing to improving fundamentals and increased …
Cambria Cannabis ETF Closes Up Shop as Investor Interest Fades
A cannabis ETF has come down from its high. Cambria Investment Management recently announced its Cambria Cannabis ETF (TOKE) is closing up shop. Shareholders have until April 17 to sell their holdings …
Cannabis operator CRON rises 46% in a year: Time to buy, sell or hold?
Shares of Cronos Group CRON have staged a strong recovery over the past year. The Canada-based cannabis operator’s shares have risen 46% in the said time frame, significantly outperforming the …
This cannabis stock will beat the market, analyst says
Haywood Capital Markets analyst Neal Gilmer has reiterated his “Buy” rating and $1.30 target price on Rubicon Organics …
Debt dominates cannabis capital raises as equity deals dry up
The cannabis industry has transitioned to a more commoditized market characterized by price declines and minimal organic growth.
1 stock I’d buy today, 1 I wouldn’t touch
Investing is about picking the right stocks and avoiding the wrong ones. While some companies are capitalizing on powerful trends, others continue to struggle despite industry tailwinds. Before I dive …
Cannabis biz could list on stock exchanges under new congressional bill (Newsletter: March 20, 2026)
THC in Medicare CBD coverage plan; Marijuana bills on VA gov’s desk; IA psilocybin; Study: Cannabis safer than alcohol & tobacco Subscribe to receive Marijuana Moment’s newsletter in your inbox every …
Recent Comments